Advertisement


Related Videos

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Welcome and Introduction to Vi3C

David A. Hyman, MD, JD, on Inclusive Shared Savings

Advertisement

Advertisement




Advertisement